WO2013127146A1 - 一种能够缓解铅毒性的植物乳杆菌及其用途 - Google Patents

一种能够缓解铅毒性的植物乳杆菌及其用途 Download PDF

Info

Publication number
WO2013127146A1
WO2013127146A1 PCT/CN2012/078799 CN2012078799W WO2013127146A1 WO 2013127146 A1 WO2013127146 A1 WO 2013127146A1 CN 2012078799 W CN2012078799 W CN 2012078799W WO 2013127146 A1 WO2013127146 A1 WO 2013127146A1
Authority
WO
WIPO (PCT)
Prior art keywords
lead
lactobacillus plantarum
ccfm8661
plantarum ccfm8661
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2012/078799
Other languages
English (en)
French (fr)
Inventor
田丰伟
陈卫
翟齐啸
张灏
赵建新
王刚
宋元达
张秋香
刘小鸣
郭敏
范大明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangnan University
Original Assignee
Jiangnan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangnan University filed Critical Jiangnan University
Priority to US14/118,867 priority Critical patent/US9320766B2/en
Priority to EP12869827.1A priority patent/EP2708599B1/en
Publication of WO2013127146A1 publication Critical patent/WO2013127146A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747Lactobacilli, e.g. L. acidophilus or L. brevis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C11/00Milk substitutes, e.g. coffee whitener compositions
    • A23C11/02Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
    • A23C11/10Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
    • A23C11/103Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins containing only proteins from pulses, oilseeds or nuts, e.g. nut milk
    • A23C11/106Addition of, or treatment with, microorganisms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C13/00Cream; Cream preparations; Making thereof
    • A23C13/12Cream preparations
    • A23C13/16Cream preparations containing, or treated with, microorganisms, enzymes, or antibiotics; Sour cream
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C19/00Cheese; Cheese preparations; Making thereof
    • A23C19/02Making cheese curd
    • A23C19/032Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L11/00Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
    • A23L11/60Drinks from legumes, e.g. lupine drinks
    • A23L11/65Soy drinks
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L19/00Products from fruits or vegetables; Preparation or treatment thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38Other non-alcoholic beverages
    • A23L2/382Other non-alcoholic beverages fermented
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/11Lactobacillus
    • A23V2400/169Plantarum
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225Lactobacillus
    • C12R2001/25Lactobacillus plantarum

Definitions

  • a Lactobacillus plantarum capable of alleviating lead toxicity and its use The invention claims priority from the Chinese invention patent application filed on February 28, 2012, and the application number is CN 2012100463235.
  • the invention belongs to the field of microbial technology. More specifically, the present invention relates to a Lactobacillus plantarum capable of alleviating lead toxicity, and to the use of said Lactobacillus plantarum.
  • Lead is a heavy metal that is extremely harmful to human health. Its unique physicochemical properties make it widely used, and it is an important chemical material in the industry, which has entered all aspects of human life; however, it is a metal element that is toxic to many organs. There is no physiological effect in the human body, and the ideal blood lead concentration should be zero. With the rapid development of the industrial, agricultural, transportation, paint, printing and electronics industries, air, soil, water and food are contaminated with lead to varying degrees. Long-term lead exposure has led to a gradual increase in lead exposure and absorption, leading to accumulation of lead in the body. Lead can act on various systems and organs of the body.
  • hematopoiesis cardiovascular, digestive, urinary, immune and other systems, which directly harm the health of the human body, including the nervous system, kidneys, Damage to the hematopoietic system and blood vessels is most pronounced.
  • Patients with lead poisoning may develop symptoms such as abdominal pain, diarrhea, vomiting, headache, dizziness, and coma, and cause physical symptoms such as vasospasm, liver and kidney damage.
  • chelating agents such as calcium disodium edetate and sodium dimercaptosuccinate for injection purposes, such as the Chinese Pharmacopoeia.
  • the second edition (2000) records the calcium disodium edetate as an antidote to heavy metal poisoning such as lead and cadmium.
  • these drugs have certain toxic side effects.
  • Calcium edetate is a broad-spectrum complexing agent with strong nephrotoxicity, and it will excrete a large amount of trace elements indispensable to the human body through the urine, such as zinc, copper, manganese, iron, etc.
  • the elements are related to the activity of many enzymes, so the large use of calcium disodium edetate can endanger people's health.
  • Sodium dimercaptosuccinate may cause digestive system dysfunction and cause headaches, Nausea, sore limbs and other symptoms.
  • Lactic acid bacteria are a general term for bacteria that ferment carbohydrates and produce lactic acid. They are widely found in naturally fermented dairy products, fermented plant foods such as kimchi, sauerkraut, silage, and human intestines. Long-term scientific research results show that probiotics represented by lactic acid bacteria are essential bacteria and important physiological functions of the human body. Their main physiological functions are: prevention and control of lactose intolerance, restoration of the balance of bacteria in the human intestinal tract, maintenance of human health Anti-tumor and cancer prevention, control of toxin levels in the body, protection of the liver and enhancement of liver detoxification. Therefore, exploring the effect of lactic acid bacteria in relieving lead toxicity can further explore the function of probiotics, develop lactic acid bacteria with higher health value, and open up new ways and solutions for using dietary strategies to alleviate the effects of lead poisoning.
  • CN 101933937A discloses a low-molecular citrus pectin having a natural chelation function and capable of excreting lead ions in an animal body
  • CN101011432 relates to bracken The use of flavonoid extract as a lead-leaching and anti-lead poisoning drug
  • CN1506070 provides a lead-containing health care product containing water-sucrose.
  • lactic acid bacteria that have the effect of alleviating lead poisoning.
  • CN101134945A discloses a Klebsiella pneumoniae Z-KAE15, which has high tolerance to lead and high adsorption, and is applied to the environment.
  • CN101252943A discloses some Lactobacillus plantarum which are used to promote absorption of iron, zinc, calcium and magnesium ions by mammals.
  • a lactic acid bacterium having a function of alleviating lead toxicity was screened, and it was proved that they have a good effect of alleviating lead poisoning in the animal model, and it is necessary to develop the practical use of these lactic acid bacteria.
  • the present inventors have finally completed the present invention on the basis of summarizing the prior art and through a large number of experimental studies.
  • the present invention has been achieved by the following technical solutions.
  • the invention relates to a lactic acid bacteria, which is identified as Lactobacillus plantarum CCFM8661 by using microbial characteristics such as morphological characteristics, culture traits and physiological and biochemical characteristics, and the strain has been in Chaoyang, Beijing on November 29, 2011.
  • the Lactobacillus plantarum CCFM8661 has the following properties:
  • the present invention also relates to the use of the Lactobacillus plantarum CCFM8661 for the preparation of a pharmaceutical composition for alleviating lead poisoning and a fermented food.
  • the pharmaceutical composition is composed of a bacterium of the genus L. facilis CCFM8661 and a pharmaceutically acceptable carrier.
  • the Lactobacillus plantarum CCFM8661 bactericidal agent is a powder obtained by preparing a bacterial liquid containing the Lactobacillus plantarum CCFM8661 by a conventional freeze-drying process or other processes, and contains 10 6 Active Lactobacillus plantarum CCFM866L above CFU/g
  • the pharmaceutically acceptable carrier is one or more selected from the group consisting of fillers, binders, wetting agents, disintegrating agents, lubricants or commonly used in pharmacy.
  • the carrier of the flavoring agent is one or more selected from the group consisting of fillers, binders, wetting agents, disintegrating agents, lubricants or commonly used in pharmacy.
  • the pharmaceutical composition is in the form of a granule, a capsule, a tablet, a pill or an oral solution.
  • the fermented food is a plant containing plant Dairy products, soy products and fruit and vegetable products produced by the fermenting agent of the Lactobacillus strain CCFM8661.
  • the starter is obtained by the following preparation steps:
  • protective agent Prepare 100 g/L skimmed milk powder, 30 mL/L glycerin, 100 g/L maltodextrin, 150 g/L trehalose, 10 g/L L by mixing water and protective agent raw materials. - a protective agent for sodium glutamate;
  • the dairy product is milk, sour cream or cheese;
  • the bean product is soy milk, soybean meal or bean paste;
  • the fruit and vegetable product is cucumber, carrot, beet, celery Or cabbage products.
  • the present invention relates to Lactobacillus plantarum CCFM8661, which was deposited on November 29, 2011 at the Institute of Microbial Culture Collection of the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Beichen West Road, Chaoyang District, Beijing. Ordinary microbiology center preservation, its deposit number is CGMCC No. 5494.
  • CCFM8661 has the following properties:
  • the cryopreserved Lactobacillus plantarum CCFM8661 of the present invention is inoculated into MRS medium (for example, a product of Qingdao Haibo Biotechnology Co., Ltd.), cultured at a temperature of 37 ° C for 24 h, and then subcultured with MRS medium for 2 h. After 3 times, 1 mL of Lactobacillus plantarum CCFM8661 culture medium was inoculated into 19 mL of MRS liquid medium with different pH values (3.0-9.0), and cultured at 37 °C for 24 h. The initial and culture were determined. OD 6 after the end. . Value, using this value to measure the concentration of cells in the bacterial culture to estimate the growth of the bacteria.
  • MRS medium for example, a product of Qingdao Haibo Biotechnology Co., Ltd.
  • the value is the absorbance of the bacterial culture solution measured by spectrophotometry at a wavelength of 600 nm, which is usually used to indicate the cell concentration in the bacterial culture solution to determine the growth of bacteria in the liquid culture.
  • the Lactobacillus plantarum CCFM8661 culture was obtained by the same culture method as described above.
  • the cells were washed twice with 1.0 mL of pH 7.2 PBS (phosphate buffer), resuspended in 1.0 mL of pH 7.2 phosphate buffer, and the resuspension was mixed with 9.0 mL of pH 2.5 artificial gastric juice, then at temperature.
  • the culture was carried out at 37 ° C, and samples were taken at the beginning (Oh) and 3 h, respectively, and plate colony counts were carried out by pouring culture on MRS agar medium, and the number of viable cells was measured and the survival rate was calculated.
  • the survival rate is the ratio of the logarithm of the viable count at the 3h in the culture solution to the logarithm of the viable count at the Oh, expressed in %.
  • the present invention screens strains with a survival rate of more than 80% for subsequent studies.
  • the tolerance of lead ions in vitro can be studied by the growth curve of Lactobacillus in different lead content media.
  • Under aseptic conditions add 0.20 g of lead chloride to 1 L of water. To a concentration of 150 mg / L of lead ion aqueous solution.
  • the MRS solid medium dry powder was dissolved using this lead ion aqueous solution to obtain a MRS liquid medium containing 150 mg/L of lead ions.
  • 50 mg/L, 500 mg/L lead ion concentration of MRS liquid medium was prepared.
  • the stationary phase of Lactobacillus plantarum CCFM8661 was inoculated into the lead-containing MRS liquid medium in an amount of 2% inoculum based on the weight of the MRS liquid medium containing lead ions.
  • the supernatant was separated and removed, pure nitric acid was added to the obtained cells, and the mixture was dissolved in a microwave digestion furnace for 20 min.
  • the obtained digestion solution was analyzed by an atomic absorption spectrometer (Spectr AA 220, Varian, USA) according to Yeager et al. Method (Yager DW, Cholak J., Henderson EW Determination of lead in biological and related materials by atomic absorption spectrometry. Environmental Science and Technology 1971; 5: 1020-1022.) Determination of lead ion content to determine the lead ion of each strain Adsorption capacity. The results of these measurements are shown in Figure 2.
  • Figure 2 clearly shows that the Lactobacillus plantarum CCFM8661 of the present invention has the highest adsorption amount of lead ions as compared with other test strains and control strains, and therefore has a good adsorption capacity for lead ions.
  • mice Twenty-five healthy male Kunming mice were randomly divided into 4 groups: negative control group, vinegar S history lead model control group, Lactobacillus plantarum CCFM8661 treatment group and edetate disodium calcium positive treatment The control group.
  • the negative control group was fed with normal drinking water; the other three groups were lg/L lead acetate solution.
  • the Lactobacillus plantarum CCFM8661 treatment group was fed daily with the concentration prepared in Example 3 of the present specification. 2.0xl0 9 cfu/mL CCFM8661 skim milk suspension, positive control group was intraperitoneally injected with 5g/L edetate disodium calcium daily.
  • the plants of the present invention were found by comparing the lead content in the blood, liver, kidney, stomach, and the body antioxidant index (SOD, MDA) of the lead exposure exposed model group and the mice fed with lead and Lactobacillus plantarum CCFM8661. Lactobacillus CCFM8661 can reduce the lead content in the blood, liver, kidney and stomach of mice, and significantly improve the antioxidant index of the mouse body.
  • Lead in the environment usually enters the body through food and respiratory pathways, causing acute or chronic toxic effects on the digestive, nervous, respiratory and immune systems, often leading to conditions such as colic, anemia and muscle spasms. In severe cases, encephalopathy can occur, or even death. Therefore, it is generally determined whether the human body is lead poisoned according to the diagnostic criteria for occupational chronic lead poisoning GBZ37-2002.
  • the term "relieving lead toxicity” should be understood as a process capable of reducing or eliminating lead poisoning in the body. According to the "Technical Specifications for Health Food Inspection and Evaluation" promulgated by the Ministry of Health in 2003, it has been proved by experiments that the use of the pharmaceutical composition containing the Lactobacillus plantarum CCFM8661 agent of the present invention can reduce the blood, liver and kidney tissues of lead poisoning mice.
  • the lead content in the body relieves the body's oxidative stress and alleviates the pathological symptoms of lead poisoning mice, increases the glutathione content in mice, reduces the malondialdehyde content, and has the health-care function of promoting lead discharge.
  • Lactobacillus plantarum CCFM8661 of the present invention has the following properties:
  • the Lactobacillus plantarum CCFM8661 of the present invention has the following biological characteristics: Bacterial characteristics: Gram-positive, cell-shaped, the cells are about 0.5-1.0 ⁇ wide, 2-4 ⁇ long, into a single, pair or into Chain, no spores, rounded at both ends.
  • Colony characteristics Significant colonies were formed on MRS medium, with a diameter of 0.3-2.0 mm, round, margins neat, milky white, opaque, smooth surface, no pigmentation.
  • the strain has a minimum growth temperature of 20 ° C, a maximum growth temperature of 40 ° C, and the best growth at a temperature of 30-37 ° C.
  • the highest and lowest initial growth pH is 9.0 and 2.5, the optimum initial pH for growth. It is 6.0; the Lactobacillus plantarum CCFM8661 strain has a relatively short delay period, starts to enter the logarithmic growth phase at about 4 h, and reaches a stable phase at 12 h.
  • the Lactobacillus plantarum CCFM8661 original strain is stored as a 30% by weight glycerol suspension at a temperature of -75 ° C, or stored as a freeze-dried powder at a temperature of 4 ° C.
  • the culture method and culture condition of the Lactobacillus plantarum CCFM8661 of the present invention can be used by culturing in a MRS medium under the condition of facultative anaerobic conditions and a temperature of 37 ° C for 18-36 h.
  • the present invention also relates to the use of the Lactobacillus plantarum CCFM8661 for the preparation of a pharmaceutical composition for alleviating lead toxicity and a fermented food.
  • the pharmaceutical composition is a Lactobacillus plantarum CCFM8661 bacterial agent and a pharmaceutically acceptable carrier.
  • the Lactobacillus plantarum CCFM8661 microbial agent is a lyophilized powder prepared by using the usual freeze-drying preparation technique to prepare the bacterial liquid containing the Lactobacillus plantarum, or by other methods such as spray drying. Powder.
  • the Lactobacillus plantarum CCFM8661 microbial agent contains 10 6 CFU/mL or more of active Lactobacillus plantarum CCFM8661.
  • the method for determining the content of Lactobacillus plantarum CCFM8661 is a MRS plate colony counting method well known to those skilled in the art.
  • the amount of the Lactobacillus plantarum CCFM8661 bacterial agent is 15-35%, preferably 18-32%, more preferably the weight of the pharmaceutical composition. 20 - 30%.
  • a pharmaceutically acceptable carrier shall mean a conventional pharmaceutical carrier in the pharmaceutical field, for example, one or more selected from the group consisting of fillers, binders, wetting agents, and granules which are commonly used in pharmacy.
  • a carrier for the release agent, lubricant or flavoring agent shall mean a conventional pharmaceutical carrier in the pharmaceutical field, for example, one or more selected from the group consisting of fillers, binders, wetting agents, and granules which are commonly used in pharmacy.
  • the filler is understood to be an excipient diluent for increasing the weight and volume of the tablet to facilitate tableting; or it should be understood as an auxiliary absorbent for absorbing excess liquid components of the material.
  • the filler is selected from the group consisting of starch, sucrose, lactose, calcium acid or microcrystalline cellulose.
  • the filler is selected from the group consisting of starch, sucrose or microcrystalline cellulose.
  • the filler is selected from starch or microcrystalline cellulose.
  • the wetting agent is understood to be a liquid in which the drug itself is non-tacky, but which can wet the drug excipient and induce its viscosity to form a granule.
  • the wetting agent is selected from the group consisting of water, ethanol, starch or syrup.
  • the wetting agent is selected from the group consisting of water, ethanol or starch.
  • the binder should be understood to mean that when the raw material drug itself is not sticky or insufficiently viscous, a viscous substance is added to facilitate granulation, and this viscous substance is called a binder.
  • the binder is selected from the group consisting of cellulose derivatives, alginates, gelatin or polyvinylpyrrolidone.
  • the binder is selected from the group consisting of cellulose derivatives, gelatin or polyvinylpyrrolidone. More preferably, the binder is selected from the group consisting of gelatin or polyvinylpyrrolidone.
  • the disintegrant is understood to be an excipient which can be added to a tablet to promote rapid disintegration of the tablet into fine particles in the gastrointestinal fluid. It is known that tablets have a high hardness after compression, and if they do not contain excipients which promote disintegration, they disintegrate slowly in the gastrointestinal tract and affect the therapeutic effect.
  • the disintegrant is selected from the group consisting of sodium carboxymethyl starch, hydroxypropyl cellulose, croscarmellose cellulose, agar, calcium carbonate or sodium hydrogencarbonate.
  • the disintegrant is selected from the group consisting of sodium carboxymethyl starch, hydroxypropyl cellulose, and croscarmyl Cellulose, agar or sodium bicarbonate.
  • the disintegrant is selected from the group consisting of sodium carboxymethyl starch, hydroxypropyl cellulose, croscarmellose cellulose or sodium hydrogencarbonate.
  • the amount of disintegrant used in the present invention is based on the total weight of the pharmaceutical composition.
  • the lubricant is understood to be a chemical substance which is advantageous for improving the fluidity of the tablet during the granulation process, preventing the tablet material from adhering to the mold of the tablet machine, and facilitating the release of the tablet. .
  • the lubricant is selected from the group consisting of talc, calcium stearate, magnesium stearate, micronized silica gel or polyethylene glycol.
  • the lubricant is selected from the group consisting of talc, calcium stearate, magnesium stearate or polyethylene glycol. More preferably, the lubricant is selected from the group consisting of talc or calcium stearate.
  • the flavoring agent is understood to be a pharmaceutical excipient which is used in medicines to improve or mask the unpleasant odor and taste of the drug, making it difficult for the patient to perceive the strong bitterness or other odor of the drug, such as spicy, irritating and the like.
  • the flavoring agent is, for example, a sweetener selected from the group consisting of monosaccharide syrup, sucrose, egg yolk, orange syrup or cherry syrup; aroma of lemon, fennel or peppermint oil; sodium alginate, gum arabic, gelatin, decyl a colloidal agent of cellulose or sodium carboxymethyl cellulose; an effervescent agent of a mixture of citric acid, tartaric acid and sodium bicarbonate.
  • a sweetener selected from the group consisting of monosaccharide syrup, sucrose, egg yolk, orange syrup or cherry syrup; aroma of lemon, fennel or peppermint oil; sodium alginate, gum arabic, gelatin, decyl a colloidal agent of cellulose or sodium carboxymethyl cellulose; an effervescent agent of a mixture of citric acid, tartaric acid and sodium bicarbonate.
  • the flavoring agent is selected from the group consisting of a sweetener of monosaccharide, sucrose, orange syrup or cherry syrup; a fragrance of lemon or peppermint oil; sodium alginate, gum arabic, gelatin or sodium carboxymethyl cellulose. a sizing agent; an effervescent mixture of tartaric acid and sodium bicarbonate.
  • the flavoring agent is selected from the group consisting of sucrose, orange syrup or cherry syrup sweetener; lemon oil fragrance; sodium alginate or gum arabic sizing agent; effervescent mixture of tartaric acid and sodium bicarbonate Agent.
  • Lactobacillus plantarum CCFM8661 bacterial agent of the present invention may be combined with a pharmaceutically acceptable carrier or excipient to prepare various dosage forms, such as granules, capsules, tablets, pills or oral solutions, wherein the pharmaceutically acceptable Acceptable carriers or excipients can be selected according to different dosage forms, and such carriers or excipients and amounts thereof used will be readily ascertainable by one of ordinary skill in the art of pharmacy.
  • the pharmaceutical granules, capsules, tablets, pills or oral solutions of the present invention are prepared by methods and apparatus commonly used by those of ordinary skill in the pharmaceutical arts.
  • the "dosage form” is generally understood to be a single-dose pharmaceutical form suitable for human use, and a single dosage form contains a predetermined active substance to achieve the desired amount, such as the Lactobacillus plantarum CCFM8661 agent of the present invention.
  • the fermented food is a dairy product, a soy product, and a fruit and vegetable product produced using a starter containing a strain of Lactobacillus plantarum CCFM8661. .
  • the preparation method of the starter is as follows:
  • protective agent Prepare 100 g/L skim milk powder, 30 mL/L glycerin, 100 g/L maltodextrin, 150 g/L trehalose, 10 g/L L- using water and protective agent raw materials.
  • a protective agent for sodium glutamate a protective agent for sodium glutamate
  • Lactobacillus plantarum CCFM8661 is inoculated into the medium at a temperature of 110-120 ° C for 8-12 min according to the inoculation amount of 2-4% by weight of the medium, and then at a temperature of 37 ° Incubate for 18 h under the conditions of C, wash 2-4 times with pH 7.2 phosphate buffer, resuspend with the protective agent to reach a concentration of 10 1G CFU/ml; then, let the suspension pre-condition at temperature 37 After culturing for 60 min, the starter was prepared by lyophilization.
  • the dairy product is milk, sour cream or cheese.
  • the milk should be understood to be cow's milk, horse's milk or reduced milk.
  • the reduced milk is prepared by reducing the total weight of the milk by 10-15% milk powder and 85-90% softening water.
  • the milk powder is a product currently widely available on the market.
  • the sour cream is a cream made by fermenting lactic acid bacteria. Sour cream has more advantages than sweet cream, the flavor is more intense, and the cream yield is higher. In addition, since the lactic acid bacteria inhibit harmful microorganisms, the risk of re-polluting microorganisms after sterilization is also low.
  • the cheese is a food of high nutritional value made by fermenting milk.
  • the soy product is soy milk, cardamom or bean paste. They are all traditional foods or seasonings in our country.
  • the fruit and vegetable product is a cucumber, carrot, beet, celery or cabbage product.
  • Lactobacillus plantarum CCFM8661 microbial starter of the present invention is used as follows:
  • the Lactobacillus plantarum CCFM8661 microbial starter of the present invention is inoculated into a raw material to be treated according to a conventional use amount, and the Lactobacillus plantarum can be made CCFM8661 ferments or survives under the temperature and pressure of reproduction. Its metabolites make the fermented products have certain characteristics such as acidity and aroma, and at the same time extend the preservation time of the products and improve the nutritional value and digestibility of the products.
  • the Lactobacillus plantarum CCFM8661 of the present invention has acid resistance, good resistance to lead ions in vitro, and can withstand a lead ion solution having a starting concentration of 150 mg/L. It also has a strong adsorption effect on lead ions, which can reduce the lead content in blood, liver, kidney and stomach of mice, significantly improve the antioxidant index of mice, and alleviate the pathological symptoms of mice with lead poisoning.
  • the plant Lactobacillus plantarum CCFM8661 has a very broad application prospect for preparing a pharmaceutical composition for relieving lead poisoning and fermented food.
  • Figure 1 is a growth curve of Lactobacillus plantarum CCFM8661 in a lead ion medium containing a starting concentration of 50 mg/L, 150 mg/L, and 500 mg/L;
  • Figure 2 shows the adsorption of lead ions by lactic acid bacteria, Bacillus subtilis and Escherichia coli.
  • CCFM8661, 14, ST-3 is Lactobacillus plantarum; 2-2 is Lactobacillus bergii; 2-3 is Lactobacillus rhamnosus LGG; 22 is Bifidobacterium bifidum; 2-3 is Des milk Bacillus.
  • Figure 3 shows the effect of Lactobacillus plantarum CCFM8661 on the reduction of lead levels in blood, liver, kidney and stomach of lead-exposed mice;
  • Example 1 Lactobacillus plantarum CCFM8661 tolerance test for lead ions
  • MRS medium is a medium well known to those skilled in the art and contains tryptone, yeast extract, glucose, sodium acetate, diammonium citrate, Tween 80, magnesium sulfate, manganese sulfate, pH 6.2 ⁇ 6.4.
  • MRS liquid medium containing 50 mg/L and 500 mg/L lead ion concentration was formulated in the same manner as described above.
  • the Lactobacillus plantarum CCFM8661 entering the stationary phase was inoculated into the lead-containing MRS liquid medium in an amount of 2% by weight based on the weight of the lead-containing MRS liquid medium, and cultured at a temperature of 37 ° C, respectively. Samples were taken at 0h, 2h, 4h, 6h, 8h, 12h, 16h, 20h, 24h, and standard plate counts were performed to obtain a growth curve of Lactobacillus plantarum CCFM8661 as shown in Fig. 1. In addition, 1 mL of the bacterial solution was inserted into the lead-free MRS liquid medium, cultured and counted under the same conditions, and the results were used as blank control results, and the results of these tests are also shown in FIG. .
  • LB medium is a medium well known to those skilled in the art and contains tryptone, yeast extract, NaCl, agar, pH 7.0.
  • the Escherichia coli and Bacillus subtilis need to be placed in a shaker at a temperature of 37 ° C for aerobic incubation for 12 h and 16 h, respectively.
  • These activated bacterial cells were shaken uniformly and centrifuged at a speed of 6000 r/min for 15 min.
  • the obtained cells were transferred to a vessel containing a 150 mg/L lead ion concentration solution, and the blank group was transferred to deionized water.
  • the volume of the liquid in the blue cap bottle was determined according to the cell mass, so that the final concentration of the cells reached lg/L.
  • the above samples were incubated at 37 ° C for 1 h.
  • Lactobacillus plantarum CCFM8661 has the strongest adsorption capacity and can adsorb 4955.1 g/g lead ions, while E. coli has poor adsorption capacity for lead ions. It can only adsorb 398 g/g lead ions, and its adsorption capacity is much lower than this.
  • Example 3 Tolerance dose experiment of Lactobacillus plantarum CCFM8661 in mice
  • the Lactobacillus plantarum CCFM8661 lyophilized powder was resuspended in skim milk powder to prepare a suspension having a concentration of 2.0 x 10 9 cf / mL.
  • About 20 g of healthy male Kunming mice were taken, and the suspension was administered once a day for one week, and the death and body weight were recorded. The results of these tests are listed in Table 1.
  • Example 4 Lactobacillus plantarum CCFM8661 reduces lead levels in lead exposed mice
  • mice Twenty to 20-25 healthy male Kunming mice were randomly divided into 4 groups: negative control group, vinegar S history lead model control group, Lactobacillus plantarum CCFM8661 treatment group and edetate disodium calcium positive treatment control group.
  • the water in the negative control group was ordinary drinking water; the water in the other three groups was lg/L lead acetate solution.
  • the mice in the Lactobacillus plantarum CCFM8661 treatment group were fed with a concentration of 2.0 ⁇ 10 9 cf /mL CCFM8661 skim milk suspension prepared in Example 3, and the positive control treatment group was intraperitoneally injected with 5 g per day. /L edetate disodium calcium agent.
  • the mice were bled and the mice were sacrificed. The liver, stomach and kidney were taken separately. After digestion by the digestion method described in Example 1, the lead content was determined by the atomic absorption spectrophotometry method used in Example 2.
  • Example 5 Recovery effect of Lactobacillus plantarum CCFM8661 on oxidative damage caused by lead exposure 40 healthy male Kunming mice of 20-25 g were randomly divided into 4 groups: negative control group, lead acetate model control group, Lactobacillus plantarum of the present invention CCFM8661 treatment group and edetate disodium calcium salt (EDTANa 2 Ca) positive control group.
  • the water in the negative control group was ordinary drinking water; the influent water in the other three groups was lg/L lead acetate solution.
  • the treatment group of the Lactobacillus plantarum CCFM8661 of the present invention was fed with the concentration of 2.0 prepared in Example 3 per day.
  • Table 2 Lactobacillus plantarum CCFM8661 of the present invention for lead poisoning
  • GSH mg/g protein
  • MDA nmol/mg protein
  • Lactobacillus plantarum CCFM8661 of the present invention can significantly reduce the lead content in the blood and various organs of lead-exposed mice, and improve the antioxidant index of mice, thereby effectively alleviating the lead toxicity effect.
  • Application Example 1 Preparation of milk containing Lactobacillus plantarum CCFM8661
  • the raw milk skim milk is heat-sterilized at 95 ° C for 20 min, then cooled to 4 ° C, and then added to the Lactobacillus plantarum CCFM8661 starter described in the present invention to a concentration of 10 6 CFU/ml or more, at 4 ° C It was stored under refrigeration and the cow's milk containing the live bacteria of Lactobacillus plantarum CCFM8661 was obtained.
  • Application Example 2 Preparation of Soymilk Containing Lactobacillus plantarum CCFM8661
  • Soybeans were soaked in soft water and soaked at a temperature of 80 ° C for 2 h to remove the soybean hulls. Next, the soaking water was drained, and then boiled with water, and incubated at a temperature higher than 80 ° C for 12 minutes. The obtained slurry was filtered through a 150-mesh sieve, followed by centrifugation, and the obtained centrifugation liquid was crude soybean milk, which was heated to a temperature of 140-150 ° C, and then the hot crude soybean milk was quickly introduced into a vacuum cooling chamber for vacuuming. The odorous substance in the crude soy milk is quickly discharged along with the water vapor.
  • Lactobacillus plantarum CCFM8661 was inoculated in a medium sterilized at a temperature of 115 ° C for 10 min according to the inoculation amount of 3% by weight of the medium, and the medium was hydrolyzed by 10% enzyme hydrolysis based on the total weight of the medium.
  • the wells 0.5% glucose, 1.5% tryptone, 0.3% yeast extract and the balance water, pH 6.8.
  • the medium inoculated with Lactobacillus plantarum CCFM8661 was cultured at 37 ° C for 18 h, washed twice with pH 7.2 phosphate buffer, and resuspended with a protective agent to a concentration of 10 1 G CFU/ml.
  • the protective agent contains 100 g/L skim milk powder, 30 mL/L glycerin, 100 g/L maltodextrin, 150 g/L trehalose and 10 g/L L-glutamate.
  • the suspension was pre-incubated for 60 min at a temperature of 37, and then freeze-dried to obtain a starter of the dairy product, the soy product, and the fruit and vegetable product.
  • Application Example 6 Using the Lactobacillus plantarum CCFM8661 of the present invention to prepare fermented milk and adding sugar, and then homogenizing at a temperature of 65 ° C and 20 MPa, and then sterilizing at a temperature of 95 ° C for 5 min, and then the temperature Lowering to 35 ° C, adding a mixed bacteria consisting of the Lactobacillus plantarum CCFM8661 starter, the commercial dry powder starter Lactobacillus bulgaricus and the commercial dry powder starter Streptococcus thermophilus, the mass ratio of which is 1:1:1, The inoculum of the mixed bacteria was 0.03 % of the weight of the fresh milk, mixed with the hook, and the mixture was incubated at a temperature of 35 ° C, and after the curd, it was chilled at a temperature of 4 ° C
  • Lactobacillus plantarum CCFM8661 bacterial powder preparation prepared by the freeze-drying method, 55.0 parts by weight of starch, 4.5 parts by weight of cellulose derivative, 12.0 parts by weight of sodium carboxymethyl starch, 0.8 parts by weight of talc, and 0.8 parts by weight of talc, respectively.
  • 1.0 part by weight of sucrose and 1.0 part by weight of water are mixed, and wet granules are prepared by a conventional method, and then tableted using a tableting machine such as that produced by Zhongnan Pharmaceutical Machinery Co., Ltd., and then used, for example, a small one produced by Qingzhou Yikang Chinese Medicine Machinery Co., Ltd.
  • the drug is dried in a drug dryer and repackaged to obtain a tablet of the present invention.
  • Application Example 8 Preparation of Pills Using Lactobacillus Plantarum CCFM8661 of the Present Invention
  • Lactobacillus plantarum CCFM8661 bacterial powder preparation prepared by the freeze-drying method 48.0 parts by weight of microcrystalline cellulose, 4.5 parts by weight of polyvinylpyrrolidone, 10.0 parts by weight of calcium carbonate and 2.8 parts by weight of magnesium stearate were respectively weighed.
  • 1.3 parts by weight of lecithin and 1.2 parts by weight of ethanol were uniformly mixed, and a conventional amount of refined honey was added to prepare a pellet of the present invention.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Agronomy & Crop Science (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Description

说 明 书
一种能够緩解铅毒性的植物乳杆菌及其用途 本发明要求申请日为 2012年 02月 28日、申请号为 CN 2012100463235 的中国发明专利申请为优先权。
【技术领域】
本发明属于微生物技术领域。 更具体地, 本发明涉及一种能够緩解铅 毒性的植物乳杆菌, 本发明还涉及所述植物乳杆菌的用途。
【背景技术】
铅是一种对人体健康极其有害的重金属。其具有的独特理化性质使其 获得广泛的应用, 在工业上是一种重要的化学材料, 从而进入了人类生活 的方方面面; 但是, 它又是一种对多个脏器具有毒性的金属元素, 在人 体内无任何生理作用, 理想血铅浓度应为零。 随着工业、 农业、 交通、油 漆、 印刷及电子产业的迅速发展, 空气、 土壤、 水及食物都不同程度地受 到了铅污染。 长期铅暴露使人们对铅的接触和吸收在逐渐增加, 导致体内 铅蓄积。 铅能够作用于全身各个系统和器官, 它的毒性与其化合物的形态 和溶解度有关, 但主要涉及造血、 心血管、 消化、 泌尿、 免疫等系统, 直 接危害人体的健康, 其中对神经系统、 肾脏、 造血系统和血管等的损害 最为显著。 铅中毒患者会出现腹痛、 腹泻、 呕吐、 头痛、 头晕、 昏迷等 症状, 并造成血管痉挛, 肝肾损伤等生理病症。
对于由铅蓄积和铅中毒引起的各种生理病症, 传统的疗法主要采用 依地酸二钠钙、 二巯基丁二酸钠等螯合剂进行注射治疗, 以达到排铅 的目的, 例如中国药典第二版( 2000年)记载了依地酸二钠钙作为铅 和镉等重金属中毒的解毒剂。 然而, 这些药物都存在着一定的毒副作 用。 依地酸二钠钙是一种广谱性络合剂, 具有较强的肾毒性, 且用药 时会经尿排出大量人体不可缺少的微量元素, 例如锌、 铜、 锰、 铁等, 而 这些元素与很多酶的活性有关, 因此大量使用依地酸二钠钙会危及人的 身体健康。二巯基丁二酸钠可能导致消化系统功能紊乱, 并造成头痛、 恶心、 四肢酸痛等症状。
鉴于传统治疗方法存在的多种问题,针对铅蓄积和铅中毒寻找一种新 的干预或治疗方法显得十分必要。乳酸菌是一类能够使碳水化合物发酵并 产生乳酸的细菌的统称, 广泛存在于自然发酵乳制品、 发酵植物食品, 如 泡菜、 酸菜、 青贮饲料以及人肠道中。 长期科学研究结果表明, 以乳酸 菌为代表的益生菌是人体必不可少的且具有重要生理功能的有益菌, 其主要生理功能有: 防治乳糖不耐症、恢复人体肠道内菌群平衡维护人 体健康、 抗肿瘤和预防癌症作用、 控制人体内毒素水平、保护肝脏并增 强肝脏的解毒等功能。 因此探索乳酸菌在緩解铅毒性效应中的效果就 可以进一步地挖掘益生菌的功能, 开发具有更高保健价值的乳酸菌, 为利用膳食策略緩解铅中毒效应开辟出新的途径和解决方案。
目前, 一些专利文献涉及排铅保健食品及其制备方法, 例如 CN 101933937A公开了一种具有自然螯合功能, 而可以将动物体内的铅离子 排出体外的低分子柑桔果胶; CN101011432 涉及蕨菜黄酮提取物在作为 排铅和緩解铅中毒药物中的应用; CN1506070提供了一种含水苏糖的排铅 保健品。但是, 目前涉及具有緩解铅中毒效应的乳酸菌专利申请文件不多, 例如 CN101134945A公开了一种肺炎克雷伯氏菌 Z-KAE15 , 它对铅具有 高耐受性、高吸附性,它应用于环境工程技术领域中。另夕卜, CN101252943A 公开了一些植物乳杆菌, 它用于促进哺乳动物吸收铁、 锌、 钙、 镁离子。
因此, 筛选出一种具有緩解铅毒性功能的乳酸菌, 并且证明它们在动 物模型中具有良好的緩解铅中毒作用, 同时研制这些乳酸菌实际的用途就 显得十分必要。
本发明人在总结现有技术的基础上, 通过大量实验研究, 终于完成了 本发明。
【发明内容】
[要解决的技术问题】
本发明的目的是提供一种植物乳杆菌 ( Lactobacillus plantarum ) CCFM8661。 本发明的另一个目的是提供所述植物乳杆菌 CCFM8661的用途。
[技术方案]
本发明是通过下述技术方案实现的。
本发明涉及一种乳酸菌, 利用形态特征、 培养性状和生理生化特征等 微生物学特性对该乳酸菌鉴定为植物乳杆菌 ( Lactobacillus plantarum ) CCFM8661 , 该菌菌株已于 2011年 11月 29日在北京市朝阳区北辰西路 1 号院 3号中国科学院微生物研究所中国微生物菌种保藏管理委员会普通微 生物中心保藏, 其保藏号为 CGMCC No.5494。
所述的植物乳杆菌 CCFM8661具有下述性质:
(1)具有耐酸性, 在 pH3.0-9.0环境条件下生长良好, 在 pH2.5环境下 存活良好;
(2)在体外含铅培养基中培养, 对铅离子有良好的耐受能力;
(3)在体外含铅水溶液中孵育, 对铅离子有良好的吸附能力;
(4)具有降低铅暴露小鼠体内铅含量与緩解铅暴露小鼠铅毒性的作用。 本发明还涉及所述的植物乳杆菌 CCFM8661在制备緩解铅中毒的 药物组合物与发酵食品中的用途。
根据本发明的一种优选实施方式,所述的药物组合物是由植物乳杆 菌 CCFM8661菌剂与在药学上可接受的载体组成的。
根据本发明的另一种优选实施方式, 所述的植物乳杆菌 CCFM8661 菌剂是将含有所述植物乳杆菌 CCFM8661的菌液通过常规冷冻干燥工艺 或其它工艺制备所得到的粉剂, 它含有 106 CFU/g以上的活性植物乳杆菌 CCFM866L
根据本发明的另一种优选实施方式,在药学上可接受的载体是一种或 多种选自在药学上通常使用的填充剂、 粘合剂、 润湿剂、 崩解剂、 润滑剂 或矫味剂的载体。
根据本发明的另一种优选实施方式, 所述的药物组合物是颗粒剂、 胶嚢剂、 片剂、 丸剂或口服液剂型。
根据本发明的另一种优选实施方式,所述的发酵食品是使用含有植物 乳杆菌 CCFM8661菌种的发酵剂生产的乳制品、 豆制品与果蔬制品。
根据本发明的另一种优选实施方式,所述的发酵剂是通过下述制备步 骤得到的:
A、 培养基的制备: 使用以所述培养基总重量计 87.7%水将 10%酶水 解脱脂乳、 0.5%葡萄糖、 1.5%胰蛋白胨与 0.3%酵母浸膏溶解, 然后调整 其 pH为 6.8 , 这样得到所述的培养基;
B、 保护剂的制备: 使用水与保护剂原料混合制备得到含有 100 g/ L 脱脂奶粉、 30 mL/ L甘油、 100 g/ L麦芽糊精、 150 g/ L海藻糖、 10 g/ L L- 谷氨酸钠的保护剂;
C、 将植物乳杆菌 CCFM8661菌种按照以所述培养基的重量计 2-4% 接种量接种到在温度 110-120°C下灭菌 8-12 min的所述培养基中, 在温度 37 °C的条件下培养 18 h, 用 pH7.2磷酸盐緩沖液清洗 2-4次, 用所述保 护剂重悬达到浓度 101Q CFU/ml; 接着, 让该悬浮液在温度 37 的条件下 预培养 60 min, 再进行冷冻干燥得到所述的发酵剂。
根据本发明的另一种优选实施方式, 所述的乳制品是牛奶、 酸奶油或 干酪; 所述的豆制品是豆奶、 豆豉或豆酱; 所述的果蔬制品是黄瓜、 胡萝 卜、 甜菜、 芹菜或圆白菜制品。
下面将更详细地描述本发明。
本发明涉及一种植物乳杆菌 ( Lactobacillus plantarum ) CCFM8661 , 该菌菌株已于 2011年 11月 29日在北京市朝阳区北辰西路 1号院 3号中 国科学院微生物研究所中国微生物菌种保藏管理委员会普通微生物中心 保藏, 其保藏号为 CGMCC No. 5494。
本发明人根据下述筛选标准, 通过大量筛选实验与分析验证, 从我国 传统食品, 例如泡菜, 发酵奶酒中筛选出的植物乳杆菌 、 Lactobacillus plantarum ) CCFM8661具有下述性质:
(1)具有耐酸性, 在 pH3.0-9.0环境条件下生长良好, 在 pH2.5环境下 存活良好;
(2)在体外含铅培养基中培养, 对铅离子有较好的耐受能力; (3)在体外含铅水溶液中孵育, 对铅离子有良好的吸附能力;
(4)具有降低铅暴露小鼠体内铅含量与緩解铅暴露小鼠铅毒性的作用。 下面将详细描述这些实验与分析认证结果。
1、 具有耐酸性, 在 pH3.0-9.0环境条件下生长良好, 在 pH2.5环境下 存活良好
将冷冻保存的本发明植物乳杆菌 CCFM8661接种于 MRS培养基 (例 如青岛海博生物技术有限公司的产品)中, 在温度 37 °C的条件下培养 24 h,再经 MRS培养液传代培养 2 ~ 3次后,取 1 mL植物乳杆菌 CCFM8661 培养液, 分别接种于 19 mL 不同 pH值(3.0-9.0 )的 MRS液体培养基中, 在温度 37 °C的条件下培养 24 h, 测定初始和培养结束后的 OD6。。值, 利 用这个值测量在细菌培养液中的细胞浓度, 从而估计细菌的生长情况。
OD6。。值是采用分光光度法在波长 600nm处测定的细菌培养液的吸光值, 它通常用于表示在细菌培养液中细胞浓度,以确定液体培养物中细菌的 生长情况。 这些试验结果证明, 植物乳杆菌 CCFM8661在 pH3.0-9.0的环 境中生长良好, 因此得以进行后续实验。
采用与前面所述的同样培养方式培养得到植物乳杆菌 CCFM8661培 养物。 其菌体用 1.0 mL pH7.2 PBS (磷酸盐緩沖液)清洗两次, 再用 1.0 mL pH7.2磷酸盐緩沖液重悬, 其重悬液与 9.0 mL pH 2.5人工胃液混合, 然后 在温度 37°C的条件下进行培养, 分别在开始 (Oh)和 3h时取样, 用 MRS琼 脂培养基浇注培养进行平板菌落计数, 测定活菌数并计算其存活率。 存活 率是在该培养液中在第 3h时的活菌数对数值与在第 Oh时活菌数对数值之 比, 以%表示。 本发明筛选存活率在 80%以上的菌株进行后续研究。
实验结果表明,植物乳杆菌 CCFM8661在 pH2.5的人工胃液环境中的 存活率在 90%以上。 由此可见, 植物乳杆菌 CCFM8661具有耐酸性, 在 pH2.5的环境下存活良好。
2、 在体外含铅培养基中培养, 对铅离子有良好的耐受能力
通过乳杆菌在不同铅含量培养基中的生长曲线可以研究其在体外对 铅离子的耐受能力。 在无菌条件下, 向 1L水中加入 0.20g氯化铅, 即得 到浓度为 150mg/L的铅离子水溶液。 使用这种铅离子水溶液溶解 MRS固 体培养基干粉得到含 150mg/L铅离子的 MRS液体培养基。 同样地, 分别 配制 50mg/L、 500mg/L铅离子浓度的 MRS液体培养基。 按照以含铅离子 的 MRS液体培养基重量计 2%接种量将进入稳定期的植物乳杆菌 CCFM8661菌液接种于所述含铅离子的 MRS液体培养基中。 在其培养过 程中, 分别在 0h、 2h、 4h、 6h、 8h、 12h、 16h、 20h、 24h时进行标准平 板计数, 从而得到如附图 1所示的植物乳杆菌 CCFM8661生长曲线。
附图 1的结果表明,本发明植物乳杆菌 CCFM8661对铅离子的具有良 好的耐受能力。
3、 在体外含铅水溶液中孵育, 对铅离子有良好的吸附能力
在无菌条件下, 按照耐酸性(在 pH3.0能够生长)的筛选标准, 从我 国传统食品, 例如泡菜, 发酵奶酒中筛选出 7株乳酸菌。 这 7株乳酸菌及 作为对照菌株的 1株大肠杆菌、 1株枯草芽孢杆菌进行了纯化和活化培养。 将上述菌株转移至 150mg/L铅溶液中, 使菌体最终浓度达到 lg/L。 将含 有上述菌株的样品在 37°C下培养 1 h, 使用 Beckman离心机以 6000 r/min 离心 20min, 再用无菌水洗涤、 离心一次。 分离除去上清液, 向得到的菌 体中加入纯硝酸, 放入微波消解炉中消解 20min, 得到的消解液使用原子 吸收光谱分析仪( Spectr AA 220, Varian, USA ), 按照 Yeager等人所述方 法 ( Yeager D. W., Cholak J., Henderson E. W. Determination of lead in biological and related materials by atomic absorption spectrometry. Environmental Science and Technology 1971; 5: 1020-1022. )测定铅离子含 量, 以确定各菌株对铅离子的吸附能力。 这些测定结果列于附图 2中。
附图 2清楚地表明, 与其它试验菌株和对照菌株相比, 本发明植物乳 杆菌 CCFM8661对铅离子的吸附量最大, 因此,对铅离子具有良好的吸附 能力。
4、 对铅暴露小鼠具有緩解铅毒性的效应
取 20-25g健康雄性昆明小鼠 40只, 随机分为 4组: 阴性对照组, 醋 S史铅模型对照组, 植物乳杆菌 CCFM8661治疗组与依地酸二钠钙阳性治 疗对照组。 阴性对照组进水为普通饮用水; 其余 3组的进水为 lg/L醋酸 铅溶液,在造成铅暴露染毒模型后,植物乳杆菌 CCFM8661治疗组每日灌 喂本说明书实施例 3制备的浓度 2.0xl09cfu/mLCCFM8661脱脂乳悬液, 阳性对照治疗组每日腹腔注射 5g/L依地酸二钠钙药剂。 实验结束后取血 并处死小鼠, 分别取肝、 胃、 肾, 在按照与前面所述的相同消化处理后, 采用上述 Yeager等人描述的原子吸收分光光度法测定铅含量。这些测定结 果列于附图 3中。
通过对铅暴露染毒模型组及共同喂食铅及植物乳杆菌 CCFM8661组 小鼠体内血液、 肝脏、 肾脏、 胃中的铅含量, 以及机体抗氧化指标(SOD, MDA ) 的比较, 发现本发明植物乳杆菌 CCFM8661能够降低小鼠血液、 肝脏、 肾脏、 胃中的铅含量, 并显著改善小鼠机体的抗氧化指标。
环境中的铅通常经食物和呼吸途径进入人体, 对消化、 神经、 呼吸和 免疫系统造成急性或慢性毒性影响, 往往导致肠绞痛、 贫血和肌肉瘫痪等 病症, 严重时可发生脑病, 甚至导致死亡。 因此, 通常根据职业性慢性铅 中毒诊断标准 GBZ37-2002确定人体是否铅中毒。
在本发明中, 术语 "緩解铅毒性" 应该理解是能够使机体内的 铅中毒现象减轻或消失的过程。依据卫生部在 2003年颁布的《保 健食品检验和评价技术规范》, 通过实验研究证明, 使用含有本 发明植物乳杆菌 CCFM8661菌剂的药物组合物能够降低铅中毒小鼠 的血、 肝脏、 肾组织中的铅含量, 緩解机体氧化应激减轻铅中毒小 鼠的病理症状, 提高小鼠体内谷胱甘肽含量, 降低丙二醛含量, 具 有促进排铅的保健功能。
研究结果表明, 本发明的植物乳杆菌 CCFM8661具有下述性能:
(1)具有耐酸性, 在 pH3.0-9.0环境条件下生长良好, 在 pH2.5环境下 存活良好;
(2)在体外含铅培养基中培养, 对铅离子有良好的耐受能力;
(3)在体外含铅水溶液中孵育, 对铅离子有良好的吸附能力;
(4)具有降低铅暴露小鼠体内铅含量与緩解铅暴露小鼠铅毒性的作用。 本发明的植物乳杆菌 CCFM8661具有下述生物学特性: 菌体特征:呈革兰氏染色阳性,细胞杆状,菌体约 0.5-1.0μηι宽, 2-4μηι 长, 成单、 成对或者成链, 不形成芽孢, 两端圆形。
菌落特征: 在 MRS培养基上形成明显的菌落, 直径在 0.3-2.0mm之 间, 圆形, 边缘整齐, 乳白色, 不透明, 表面湿润光滑, 不产生色素。
生长特性: 该菌株的最低生长温度为 20°C , 最高生长温度为 40 °C , 在温度 30-37 °C下生长最佳, 最高和最低初始生长 pH为 9.0和 2.5 , 最适 生长初始 pH为 6.0; 本发明植物乳杆菌 CCFM8661菌株的延迟期相对较 短, 4 h左右开始进入对数生长期, 12 h就达到稳定期。
本发明植物乳杆菌保存方法:
所述植物乳杆菌 CCFM8661原始菌种在温度 - 75°C下以 30 %重量百 分数的甘油悬液形式保存, 或者在温度 4 °C下以冷冻干燥菌粉的形式保存 备用。
本发明植物乳杆菌 CCFM8661培养方法与培养条件: 在 MRS培养基 中在兼性厌氧条件与温度 37°C的条件下培养 18-36 h即可使用。
本发明还涉及所述的植物乳杆菌 CCFM8661在制备緩解铅毒性的 药物组合物与发酵食品中的用途。
所述的药物组合物是植物乳杆菌 CCFM8661菌剂与在药学上可接 受的载体组成的。
根据本发明,所述的植物乳杆菌 CCFM8661菌剂是采用通常的冷冻干 燥制备技术将含有所述的植物乳杆菌的菌液制成的冻干粉剂,或是采用其 它方法如喷雾干燥法制备得到的粉剂。
所述的植物乳杆菌 CCFM8661菌剂含有 106 CFU/mL以上的活性植物 乳杆菌 CCFM8661。
植物乳杆菌 CCFM8661含量测定方法是本技术领域的技术人员熟知 的 MRS平板菌落计数法。
在所述的药物组合物中,所述植物乳杆菌 CCFM8661菌剂的量是所 述药物组合物重量的 15-35% , 优选地是 18-32% , 更优选地是 20 - 30%。
根据本发明,在药学上可接受的载体应该是指在药学领域中的常规药 物载体, 例如是一种或多种选自在药学上通常使用的填充剂、 粘合剂、润 湿剂、 崩解剂、 润滑剂或矫味剂的载体。
根据本发明,所述的填充剂应该理解是用来增加片剂重量和体积而便 于压片的辅料稀释剂; 或者应该理解是用以吸收原料中多余液体成分的辅 料吸收剂。
所述的填充剂选自淀粉、 蔗糖、 乳糖、 酸钙或微晶纤维素。
优选地, 所述的填充剂选自淀粉、 蔗糖或微晶纤维素。
更优选地, 所述的填充剂选自淀粉或微晶纤维素。
根据本发明, 所述的润湿剂应该理解是药物本身无粘性, 但可润湿其 药物原辅料并诱发其粘性而制成颗粒的液体。
所述的润湿剂选自水、 乙醇、 淀粉或糖浆。
优选地, 所述的润湿剂选自水、 乙醇或淀粉。
本发明使用润湿剂的量是以所述药物组合物总重量计 0. 1 -3. 0%。 根据本发明,所述的粘合剂应该理解是当原料药物本身无粘性或粘性 不足时, 需加入粘性物质以便于制粒, 这种粘性物质称为粘合剂。
所述的粘合剂选自纤维素衍生物、 藻酸盐、 明胶或聚乙烯吡咯烷酮。 优选地, 所述的粘合剂选自纤维素衍生物、 明胶或聚乙烯吡咯烷酮。 更优选地, 所述的粘合剂选自明胶或聚乙烯吡咯烷酮。
本发明使用粘合剂的量是以所述药物组合物总重量计 0. 5 -5. 0%。 根据本发明,所述的崩解剂应该理解是一种能够加入片剂中而促进其 片剂在胃肠液中快速崩解成细小粒子的辅料。 人们知道, 片剂经过压缩后 的硬度大, 如果其中不含有可以促进崩解作用的辅料, 它在胃肠道中崩解 很慢, 影响疗效。
所述的崩解剂选自羧曱基淀粉钠、 羟丙纤维素、 交联羧曱基纤维素、 琼脂、 碳酸钙或碳酸氢钠。
优选地, 所述的崩解剂选自羧曱基淀粉钠、 羟丙纤维素、 交联羧曱基 纤维素、 琼脂或碳酸氢钠。
更优选地, 所述的崩解剂选自羧曱基淀粉钠、 羟丙纤维素、 交联羧曱 基纤维素或碳酸氢钠。
本发明使用崩解剂的量是以所述药 物组合物总重量计
5. 0 - 15. 0%。
根据本发明,所述的润滑剂应该理解是一种有利于提高片剂在制粒过 程中的流动性, 防止片剂材料粘附在制片机模子上, 有利于片剂脱模的化 学物质。
所述的润滑剂选自滑石粉、 硬脂酸钙、 硬脂酸镁、 微粉硅胶或聚乙二 醇。
优选地,所述的润滑剂选自滑石粉、硬脂酸钙、硬脂酸镁或聚乙二醇。 更优选地, 所述的润滑剂选自滑石粉或硬脂酸钙。
本发明使用润滑剂的量是以所述药物组合物总重量计 0. 5-3. 0%。 根据本发明,所述的矫味剂应该理解是在药品中用以改善或屏蔽药物 不良气味和味道, 使病人难以觉察药物强烈苦味或其它异味, 例如辛辣、 刺激等的药用辅料。
所述的矫味剂例如选自单糖浆、 蔗糖、 卵磚脂、 橙皮糖浆或樱桃糖 浆的甜味剂; 柠檬、 茴香或薄荷油的芳香剂; 海藻酸钠、 阿拉伯胶、 明胶、 曱基纤维素或羧曱基纤维素钠的胶浆剂; 柠檬酸、 酒石酸与碳 酸氢钠混合物的泡腾剂。
优选地, 所述的矫味剂选自单糖浆、 蔗糖、 橙皮糖浆或樱桃糖浆的 甜味剂; 柠檬或薄荷油的芳香剂; 海藻酸钠、 阿拉伯胶、 明胶或羧曱 基纤维素钠的胶浆剂; 酒石酸与碳酸氢钠混合物的泡腾剂。
更优选地,所述的矫味剂选自蔗糖、橙皮糖浆或樱桃糖浆的甜味剂; 柠檬油芳香剂; 海藻酸钠或阿拉伯胶的胶浆剂; 酒石酸与碳酸氢钠混 合物的泡腾剂。
本发明使用矫味剂的量是以所述药 物组合物总重量计 0. 5%- 2. 0%。 本发明的植物乳杆菌 CCFM8661菌剂可以与在药学上可接受的载体 或赋形剂组合制成各种剂型, 例如颗粒剂、胶嚢剂、 片剂、 丸剂或口服液, 其中在药学上可接受的载体或赋形剂可以根据不同剂型进行选择,所使用 的这些载体或赋形剂及其用量对于制药技术领域的普通技术人员都是容 易确定的, 也是显而易见的。
在本发明中,采用制药技术领域的普通技术人员熟知的普遍使用的方 法和设备制备本发明药物颗粒剂、 胶嚢剂、 片剂、 丸剂或口服液。
所述的 "剂型" 一般应该理解是适用于人的单剂量药物形式, 单个剂 型含有为达到所需药量的预定活性物质, 例如本发明的植物乳杆菌 CCFM8661菌剂。
在本发明中,所述的发酵食品是使用含有植物乳杆菌 CCFM8661菌种 的发酵剂生产的乳制品、 豆制品与果蔬制品。。
所述发酵剂的制备方法如下:
A、 培养基的制备: 使用以所述培养基总重量计 87.7%水将 10%酶水 解脱脂乳、 0.5%葡萄糖、 1.5%胰蛋白胨与 0.3%酵母浸膏溶解, 然后调整 其 pH为 6.8, 这样得到所述的培养基;
B、 保护剂的制备: 使用水与保护剂原料制备得到含有 100 g/ L脱脂 奶粉、 30 mL/ L甘油、 100 g/ L麦芽糊精、 150 g/ L海藻糖、 10 g/ L L-谷 氨酸钠的保护剂;
C、 将植物乳杆菌 CCFM8661按照以所述培养基的重量计 2-4%接种 量接种到在温度 110-120°C下灭菌 8-12 min的所述培养基中, 然后在温度 37 °C的条件下培养 18 h, 用 pH7.2磷酸盐緩沖液清洗 2-4次, 用所述保 护剂重悬达到浓度 101GCFU/ml; 接着, 让该悬浮液在温度 37 的条件下 预培养 60 min, 再采用冻干法制成所述的发酵剂。
所述的乳制品是牛奶、 酸奶油或干酪。
在本发明中, 所述的牛奶应该理解是牛乳、 马乳或还原乳。 所述的还 原乳是用以还原乳总重量计 10-15%奶粉与 85-90%软化水配制的。 所述的 奶粉是目前市场上广泛销售的产品。 所述的酸奶油是稀奶油经乳酸菌发酵制成的奶油。酸奶油比甜奶油有 更多的优越性, 香味更浓郁, 奶油产量也更高; 另外由于乳酸菌抑制了有 害微生物, 所以消毒杀菌后再次污染微生物的风险也较低。
所述的干酪是由牛奶经发酵制成的一种营养价值很高的食品。
所述的豆制品是豆奶、豆豉或豆酱。 它们都是我国的传统食品或调味 口口。
所述的果蔬制品是黄瓜、 胡萝卜、 甜菜、 芹菜或圆白菜制品。
在生产乳制品、 豆制品与果蔬制品时, 按照下述方法使用本发明的植 物乳杆菌 CCFM8661菌剂发酵剂:
通常, 在生产乳制品、 豆制品和果蔬制品的常规生产过程中, 把本发 明的植物乳杆菌 CCFM8661菌剂发酵剂按照常规使用量接种到待处理的 原料中, 在能够使所述植物乳杆菌 CCFM8661繁殖的温度、 压力下进行 发酵或存活,其代谢产物使发酵制品具有一定的酸度、香味等优异特性, 同时使产品延长了保藏时间, 改善了产品营养价值和消化性。
[有益效果】
本发明的植物乳杆菌 CCFM8661具有耐酸性,在体外对铅离子有良好 的耐受能力, 能够耐受起始浓度为 150mg/L的铅离子溶液。 并且对铅离子 有较强的吸附作用, 可降低小鼠血液、 肝脏、 肾脏、 胃中的铅含量, 显著 改善小鼠机体的抗氧化指标, 緩解铅中毒小鼠的病理症状。 所述的植物乳 杆菌 CCFM8661用于制备緩解铅中毒的药物组合物与发酵食品,具有 非常广泛的应用前景。
【附图说明】
图 1是植物乳杆菌 CCFM8661于含起始浓度为 50mg/L, 150mg/L, 500mg/L的铅离子培养基中的生长曲线;
图 2是乳酸菌、 枯草芽孢杆菌和大肠杆菌对铅离子的吸附情况。
其中: CCFM8661、 14、 ST-3为植物乳杆菌; 2-2 为加氏乳杆菌; 2-3 为鼠李糖乳杆菌 LGG; 22 为两歧双歧乳杆菌; 2-3为德氏乳杆菌。
7/ n //7/ 枯草芽孢杆菌、 E.coli、大肠杆菌)作为实验对照菌株。 图 3 是植物乳杆菌 CCFM8661对铅暴露小鼠血液, 肝脏, 肾脏, 胃 中铅水平的降低作用;
a, b, c, d表示不同字母所代表的组别都存在显著性差异(P<0.05 )。
【具体实施方式】
实施例 1: 植物乳杆菌 CCFM8661对铅离子的耐受能力实验
在无菌条件下, 向 1L水中加入 0.20g氯化铅, 得到 150mg/L的铅离 子水溶液。 使用这种铅离子水溶液溶解 MRS培养基固体配料, 得到含 150mg/L铅离子的 MRS液体培养基。 MRS培养基是本技术领域的技术人 员熟知的培养基, 它含有胰蛋白胨、 酵母浸膏、 葡萄糖、 醋酸钠、 柠檬酸 二铵、 吐温 80、 硫酸镁、 硫酸锰, pH 6.2 ~ 6.4。
以与前面描述的同样方式配制含有 50mg/L与 500mg/L铅离子浓度的 MRS液体培养基。 将进入稳定期的植物乳杆菌 CCFM8661按照以含铅的 MRS液体培养基重量计 2%接种量接种于所述的含铅 MRS液体培养基中, 在温度 37°C的条件下进行培养, 分别在 0h、 2h、 4h、 6h、 8h、 12h、 16h, 20h、 24h时取样, 进行标准平板计数, 得到如附图 1所示的植物乳杆菌 CCFM8661生长曲线。另夕卜,将 1 mL所述的菌液接入不含铅的 MRS液体 培养基中, 在同样条件下进行培养并计数, 其结果作为空白对照结果,这 些试验结果也列于附图 1中。
由附图 1可以看出,在 150mg/L铅离子浓度下,植物乳杆菌 CCFM8661 虽然在开始时生长受到抑制, 但随后其生长量迅速增加, 在 24h时生长量 甚至超过了空白对照组, 因此,其结果表明植物乳杆菌 CCFM8661对铅离 子具有良好的耐受能力。 实施例 2: 植物乳杆菌 CCFM8661对铅离子的吸附能力实验
按照耐酸性(在 pH3.0环境中能够生长)的筛选标准, 从我国传统食 品, 例如泡菜, 发酵奶酒中筛选出 7株乳酸菌, 将这 7株乳酸菌与作为对 照菌株的 1株大肠杆菌和 1株枯草芽孢杆菌在无菌条件下进行纯化和活 化, 纯化和活化时乳酸菌使用 MRS培养基, 大肠杆菌和枯草芽孢杆菌使 用 LB培养基。 LB培养基是本技术领域的技术人员熟知的培养基, 它含 有胰蛋白胨、 酵母浸膏、 NaCl、 琼脂, pH7.0。 另外, 所述的大肠杆菌和 枯草芽孢杆菌还需置于摇床中在温度 37 °C的条件下分别进行好氧培养 12h和 16h。将这些活化菌液振荡均匀,以转速 6000 r/min进行离心 15min。 得到的菌体转移到装有 150mg/L铅离子浓度溶液的容器中,而空白组则转 移到去离子水中。 根据菌体质量确定蓝盖瓶中液体的体积, 使菌体的最终 浓度达到 lg/L。将以上样品于温度 37°C下培养 1 h。使用 Beckman离心机 以转速 6000 r/min离心 20min, 再用无菌水洗涤、 离心一次。 分离除去上 清液, 向得到的菌体中加入纯硝酸, 放入微波消解炉中消解 20min, 得到 的消解液使用原子吸收光谱分析仪 ( Spectr AA 220, Varian, USA )按照 Yeager 等人所述方法 ( Yeager D. W., Cholak J., Henderson E. W. Determination of lead in biological and related materials by atomic absorption spectrometry. Environmental Science and Technology 1971; 5: 1020-1022. ) 测定铅离子含量, 以确定不同菌株吸附铅离子的能力。
其试验结果如附图 2所示。 由附图 2可以看出, 不同的菌种对铅离子 的吸附能力差异较大。其中植物乳杆菌 CCFM8661的吸附能力最强,可吸 附 4955.1 g/g铅离子, 而大肠杆菌对铅离子的吸附能力较差, 只能吸附 398 g/g的铅离子, 其吸附能力远低于本发明的植物乳杆菌 CCFM8661。 实施例 3: 植物乳杆菌 CCFM8661灌喂小鼠的耐受剂量实验
将植物乳杆菌 CCFM8661冻干菌粉重悬于脱脂乳粉中, 制成浓度为 2.0x l09cf /mL的悬液。 取约 20g健康雄性昆明小鼠 10只, 每日给予该浓 度悬液灌胃一次, 观察一周, 记录死亡和体重情况。 这些试验结果列于表 1中。
表 1 : 喂食浓度 2.0x l09cfu/mL的植物乳杆菌 CCFM8661
对小鼠体重的变化情况
时间 (天) 1 2 3 4 5 6 7 体重 (g ) 21.2±1.5 21.9±2.1 22.5±2.2 23.5±2.1 24.2±1.9 24.9±1.9 25.7±1.8 死亡情况 - - - - - - 注: - : 小鼠无死亡
表 1 中的这些结果表明, 喂食浓度 2.0x l09cfu/mL的植物乳杆菌 CCFM8661未对小鼠造成明显影响, 体重明显上升, 无死亡现象产生。小 鼠外观无明显病理症状。
实施例 4:植物乳杆菌 CCFM8661对铅暴露小鼠体内铅水平的降低作 用
取 20-25g健康雄性昆明小鼠 40只, 随机分为 4组: 阴性对照组, 醋 S史铅模型对照组, 植物乳杆菌 CCFM8661治疗组与依地酸二钠钙阳性治 疗对照组。 阴性对照组进水为普通饮用水; 其余 3组的进水为 lg/L醋酸 铅溶液。在造成铅暴露染毒模型后,植物乳杆菌 CCFM8661治疗组小鼠每 日灌喂实施例 3制备的浓度 2.0x l09cf /mLCCFM8661脱脂乳悬液, 阳性 对照治疗组小鼠每日腹腔注射 5g/L依地酸二钠钙药剂。 实验结束后取血 并处死小鼠, 分别取肝、 胃、 肾, 采用实施例 1描述的消化方法进行消化 后, 按照实施例 2采用的原子吸收分光光度法测定其铅含量。
这些试验结果如附图 3所示。 由附图 3可以看出, 本发明的植物乳杆 菌 CCFM8661治疗组和依地酸二钠钙阳性治疗对照组中小鼠血液、肝脏、 胃、 肾脏中的铅含量均比阴性对照组高, 但均低于铅模型对照组。 本发明 植物乳杆菌 CCFM8661治疗组相对于铅模型对照组,其血液及各器官中的 铅含量明显低,均具有显著性( P < 0.05 ), 这也说明植物乳杆菌 CCFM8661 干预确实具有降低铅暴露小鼠体内铅含量的作用。 实施例 5:植物乳杆菌 CCFM8661对铅暴露导致氧化损伤的恢复作用 取 20-25g的健康雄性昆明小鼠 40只, 随机分为 4组: 阴性对照组, 醋酸铅模型对照组, 本发明植物乳杆菌 CCFM8661治疗组与依地酸二钠 钙盐(EDTANa2Ca ) 阳性治疗对照组。 阴性对照组进水为普通饮用水;其 余 3组的进水为 lg/L醋酸铅溶液, 在造成铅染毒模型后, 本发明植物乳 杆菌 CCFM8661治疗组每日灌喂实施例 3制备的浓度 2.0x l09cf /mL的 CCFM8661脱脂乳悬液, 阳性对照治疗组每日腹腔注射 5g/L依地酸二钠 钙盐药剂。实 3 结束后取血并处死小鼠,取肝,采用 Ellmam的方法( Ellmam G.C. Tissue sulfhydryl groups. Archives of biochemistry and biophysics 82(1): 70-77. ) 及南京建成生物工程研究所生产的丙二醛试剂盒测定谷胱甘肽 ( GSH )和丙二醛(MDA ) 的水平。
这些试验结果列于下表 2中。
表 2: 本发明植物乳杆菌 CCFM8661对铅中毒
导致氧化损伤的恢复作用
组 (肝) GSH (mg/g蛋白) MDA (nmol/mg蛋白) 对照 2.69士 0.40 0·11±0·04
仅铅 1.63士 0.75a 0.18±0.03a
铅 + CCFM8661 2.46士 0.71b 0.16±0.04b
铅 +EDTANa2Ca 2.15±0.50c 0.15±0.03e
注: a: 与空白对照组比较 P<0.05; b: 与铅模型组比较 PO.05; c: 与铅模 型组比较 PO.05
由表 2的结果可以看出,本发明植物乳杆菌 CCFM8661干预组的小鼠 肝样品中, GSH含量高于铅模型对照组, 但低于空白对照组; MDA含量 与铅模型对照组相比有所降低, 但高于空白对照组。 其中与铅模型对照组 相比, 本发明植物乳杆菌 CCFM8661治疗组的 GSH及 MDA含量都具有 显著性差异(P < 0.05 )。 谷胱甘肽(GSH )是一种生物体内的重要的抗氧 化剂, 丙二醛( MDA )是一种生物体内的自由基与脂质发生过氧化反应 的终产物, 是生物体内氧化应激损伤的一种标志物。 如表 2所示, 相比于 空白对照组, 铅模型组的谷胱甘肽(GSH ) 浓度出现明显降低, 丙二醛 ( MDA ) 浓度显著升高, 这些结果充分说明, 铅暴露确实造成了小鼠体 内的氧化应激反应。 而相比于铅模型组, 本发明植物乳杆菌 CCFM8661 治疗组中的谷胱甘肽含量显著升高, 丙二醛含量显著下降, 这些结果清楚 地说明本发明植物乳杆菌 CCFM8661的治疗确实緩解了铅毒性造成的氧 化损伤。
以上这些动物实验表明,本发明植物乳杆菌 CCFM8661能够显著降低 铅暴露小鼠血液和各器官中的铅含量, 改善小鼠的抗氧化指标, 从而有效 緩解铅毒性效应。 应用实施例 1: 制备含有植物乳杆菌 CCFM8661的牛乳
将原料乳脱脂奶在 95°C热杀菌 20min, 然后冷却至 4°C , 再加入在本 发明书描述的植物乳杆菌 CCFM8661发酵剂, 使其浓度达到 106 CFU/ml 以上, 在 4°C下冷藏保存, 于是得到含有植物乳杆菌 CCFM8661活菌的牛 乳。 应用实施例 2: 制备含有植物乳杆菌 CCFM8661的豆奶
采用软水浸泡大豆, 在温度 80°C下浸泡 2 h, 再去除大豆皮。 接着, 沥去浸泡水, 再加沸水磨浆, 并在高于 80°C的温度条件下保温 12min。得 到的浆料用 150目筛网过滤, 接着进行离心分离, 得到的离心液即为粗豆 奶, 再将它加热到温度 140-150°C , 然后将热粗豆奶迅速导入真空冷却室 进行抽真空, 所述粗豆奶中的异味物质随着水蒸汽迅速排出。 经过真空脱 气后, 将其温度降至约 37°C , 再接入本发明的植物乳杆菌 CCFM8661工 作发酵剂, 使其浓度达到 106 CFU/ml以上, 在温度 4°C下冷藏保存, 于是 得到含有植物乳杆菌 CCFM8661活菌的豆奶。 应用实施例 3: 制备含有植物乳杆菌 CCFM8661制造的果蔬饮料 选用新鲜蔬菜洗净后榨汁, 接着进行高温瞬间灭菌, 在温度 140°C下 高温热杀菌 2秒后,立即降温到温度约 37°C ,再接入本发明制备的植物乳 杆菌 CCFM8661菌剂发酵剂,使其浓度达到 106 CFU/mL以上,在温度 4°C 下冷藏保存, 于是得到含有植物乳杆菌 CCFM8661活菌的果蔬饮料。 应用实施例 4: 制备含有植物乳杆菌 CCFM8661的胶嚢制品 将本发明的植物乳杆菌 CCFM8661在 MRS培养基中培养 24 h, 在温 度 4°C与 4000 r/min的条件下离心 20 min, 用 pH7.2磷酸盐緩沖液沖洗两 次, 其菌体用灭菌脱脂乳重悬, 使最终菌体浓度达到 lxl01G ~ 3xl01G cf /mL。 将菌悬液加入到以重量计 3%海藻酸钠溶液中, 充分搅拌, 使得 细胞均匀地分散于海藻酸钠溶液中, 然后将此混合液挤压到以重量计 2% 氯化钙溶液中形成胶粒, 静止固化 30min, 过滤收集胶粒, 将收集得到的 胶粒进行冷冻干燥 48h, 得到含有植物乳杆菌 CCFM8661的粉剂, 把这种 粉剂装入到在目前市场上销售的药用胶嚢中, 得到所述的胶嚢制品。 应用实施例 5:使用本发明植物乳杆菌 CCFM8661制备用于生产乳制 品、 豆制品以及果蔬制品的发酵剂
将植物乳杆菌 CCFM8661按照以所述培养基重量计 3%接种量接种于 在 115°C温度下灭菌 lO min的培养基中,该培养基由以该培养基总重量计 10%酶水解脱脂孔、 0.5%葡萄糖、 1.5%胰蛋白胨、 0.3%酵母浸膏和余量水 组成, pH6.8。然后,让接种植物乳杆菌 CCFM8661的培养基在温度 37 °C 的条件下培养 18 h, 用 pH7.2磷酸盐緩沖液清洗两次, 再用保护剂重悬达 到浓度 101GCFU/ml。所述的保护剂含有 100 g/ L脱脂奶粉、 30 mL/ L甘油、 100 g/ L麦芽糊精、 150 g/ L海藻糖与 10 g/ L L-谷氨酸钠。
接着, 让该悬浮液在温度 37 的条件下预培养 60 min, 再进行冷冻 干燥, 得到所述的乳制品、 豆制品以及果蔬制品的发酵剂。 应用实施例 6: 利用本发明植物乳杆菌 CCFM8661制备发酵乳 鲜奶加糖溶解后, 在温度 65°C与 20 MPa条件下进行均质, 然后在温 度 95°C下保温杀菌 5 min, 再将温度降到 35°C , 加入由本发明植物乳杆菌 CCFM8661发酵剂、商业干粉发酵剂保加利亚乳杆菌和商业干粉发酵剂嗜 热链球菌组成的混合菌, 它们的质量比例为 1:1:1 , 所述混合菌的接种量为 鲜奶重量的 0.03 % , 混勾, 在温度 35°C下保温发酵, 凝乳后, 在温度 4°C 下冷藏 24 h, 得到所述的发酵乳。 应用实施例 7: 利用本发明植物乳杆菌 CCFM8661制备片剂
分别称取采用冷冻干燥方法制备的本发明植物乳杆菌 CCFM8661菌 粉制剂 25.7重量份、 淀粉 55.0重量份、 纤维素衍生物 4.5重量份、羧曱基 淀粉钠 12.0重量份、 滑石粉 0.8重量份、 蔗糖 1.0重量份与水 1.0重量份, 混合, 采用常规方法制成湿颗粒, 然后使用例如中南制药机械厂生产的压 片机进行压片,然后使用例如青州市益康中药机械有限公司生产的小型药 物干燥机中进行干燥, 再包装得到本发明的片剂。 应用实施例 8: 利用本发明植物乳杆菌 CCFM8661制备丸剂
分别称取采用冷冻干燥方法制备的本发明植物乳杆菌 CCFM8661菌 粉制剂 32.2重量份、微晶纤维素 48.0重量份、聚乙烯吡咯烷酮 4.5重量份, 碳酸钙 10.0重量份、 硬脂酸镁 2.8重量份、 卵磷脂 1.3重量份与乙醇 1.2 重量份, 混合均匀, 再加入常规量的炼蜜制成本发明的丸剂。

Claims

权 利 要 求 书
1、 一种植物乳 4干菌 Lactobacillus plantarum、 MA , 该菌株已 于 2011年 11月 29日在中国微生物菌种保藏管理委员会普通微生物菌种 保藏中心保藏, 其保藏号为 CGMCC 5494。
2、 根据权利要求 1所述的植物乳杆菌 CCFM8661 , 其特征在于它具 有下述性质:
(1)具有耐酸性, 在 pH3.0-9.0环境条件下生长良好, 在 pH2.5环境下 存活良好;
(2)在体外含铅培养基中培养, 对铅离子有良好的耐受能力;
(3)在体外含铅水溶液中孵育, 对铅离子有良好的吸附能力;
(4)具有降低铅暴露小鼠体内铅含量与緩解铅暴露小鼠铅毒性的作用。
3、 根据权利要求 1所述的植物乳杆菌 CCFM8661在制备緩解铅毒 性的药物组合物与发酵食品中的用途。
4、 根据权利要求 3所述的用途, 其特征在于所述的药物组合物是 由植物乳杆菌 CCFM8661菌剂与在药学上可接受的载体组成的。
5、 根据权利要求 4所述的用途, 其特征在于所述的植物乳杆菌 CCFM8661菌剂是将含有所述植物乳杆菌 CCFM8661的菌液通过常规冷 冻干燥工艺或其它工艺制备所得到的粉剂, 它含有 106 CFU/g以上的活性 植物乳杆菌 CCFM8661。
6、 根据权利要求 4所述的用途, 其特征在于在药学上可接受的载体 是一种或多种选自在药学上通常使用的填充剂、粘合剂、润湿剂、崩解剂, 润滑剂或矫味剂的载体。
7、根据权利要求 3或 4所述的用途,其特征在于所述的药物组合物 是颗粒剂、 胶嚢剂、 片剂、 丸剂或口服液剂型。
8、 根据权利要求 2所述的用途, 其特征在于所述的发酵食品是使用 含有植物乳杆菌 CCFM8661菌种的发酵剂生产的乳制品、豆制品与果蔬制 口口。
9、 根据权利要求 8所述的用途, 其特征在于所述的发酵剂是通过下 述制备步骤得到的:
A、 培养基的制备: 使用以所述培养基总重量计 87.7%的水将 10%酶 水解脱脂乳、 0.5%葡萄糖、 1.5%胰蛋白胨与 0.3%酵母浸膏溶解, 然后调 整其 pH为 6.8, 这样得到所述的培养基;
B、 保护剂的制备: 使用水与保护剂原料混合制备得到含有 100 g/ L 脱脂奶粉、 30 mL/ L甘油、 100 g/ L麦芽糊精、 150 g/ L海藻糖、 10 g/ L L- 谷氨酸钠的保护剂;
C、 将植物乳杆菌 CCFM8661菌种按照以所述培养基的重量计 2-4% 接种量接种到在温度 110-120°C下灭菌 8-12 min的所述培养基中, 然后在 温度 37 °C的条件下培养 18 h, 用 pH7.2磷酸盐緩沖液清洗 2-4次, 用所 述的保护剂重悬达到浓度 101GCFU/ml; 接着, 让该悬浮液在温度 37 °〇的 条件下预培养 60 min, 再进行冷冻干燥得到所述的发酵剂。
10、 根据权利要求 8所述的用途, 其特征在于所述的乳制品是牛奶、 S史奶油或干酪; 所述的豆制品是豆奶、 豆豉或豆酱; 所述的果蔬制品是黄 瓜、 胡萝卜、 甜菜、 芹菜或圆白菜制品。
PCT/CN2012/078799 2012-02-28 2012-07-18 一种能够缓解铅毒性的植物乳杆菌及其用途 Ceased WO2013127146A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US14/118,867 US9320766B2 (en) 2012-02-28 2012-07-18 Protective effects and application of a lactobacillus plantarum on the alleviation of lead toxicity
EP12869827.1A EP2708599B1 (en) 2012-02-28 2012-07-18 Lactobacillus plantarum able to relieve lead toxicity and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210046323.5 2012-02-28
CN2012100463235A CN102586148B (zh) 2012-02-28 2012-02-28 一种能够缓解铅毒性的植物乳杆菌及其用途

Publications (1)

Publication Number Publication Date
WO2013127146A1 true WO2013127146A1 (zh) 2013-09-06

Family

ID=46475387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/078799 Ceased WO2013127146A1 (zh) 2012-02-28 2012-07-18 一种能够缓解铅毒性的植物乳杆菌及其用途

Country Status (4)

Country Link
US (1) US9320766B2 (zh)
EP (1) EP2708599B1 (zh)
CN (1) CN102586148B (zh)
WO (1) WO2013127146A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107129951A (zh) * 2017-06-19 2017-09-05 青岛科拓恒通乳酸菌产业化开发研究院有限公司 一种提高盐碱地花生微量养分利用率的复合乳酸菌制剂及其应用
CN115838650A (zh) * 2022-05-06 2023-03-24 佛山市孛特碧欧微生物科技有限公司 植物乳杆菌及其应用

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827796B (zh) 2012-09-03 2013-10-30 江南大学 一种具有排镉功能的植物乳杆菌及其用途
CN102960620B (zh) * 2012-12-12 2013-09-11 江南大学 一种直投式酸面团发酵剂及其制备方法与用途
KR102250588B1 (ko) * 2013-07-02 2021-05-12 오스트리아노바 싱가포르 피티이 리미티드 캡슐화 세포의 동결-건조 방법, 동결 건조된 캡슐화 세포, 동결 건조된 캡슐화 세포를 함유하는 조성물, 및 상기 세포 및 조성물의 용도
CN104611278B (zh) * 2015-02-27 2017-07-14 江南大学 一种能够缓解铝毒性的植物乳杆菌及其用途
CN104938627A (zh) * 2015-06-12 2015-09-30 柳陈坚 一种乳酸菌发酵功能性酸奶的制备方法
CN105274044A (zh) * 2015-11-05 2016-01-27 胡文锋 一种灭活乳酸菌细胞及其在食品中的应用
CN105285514A (zh) * 2015-11-24 2016-02-03 江南大学 一种能够缓解罗非鱼铅毒性的植物乳杆菌饲料
CN105724985B (zh) * 2016-01-29 2019-03-05 江南大学 一种同时延缓维生素c降解和去除重金属铅的果蔬汁改良方法
CN105831771B (zh) * 2016-03-23 2019-04-23 江南大学 一种具有缓解铅毒性功能的益生菌和微量元素的膳食补充剂
CN105901741B (zh) * 2016-03-23 2019-03-19 江南大学 一种具有缓解铅毒性功能的益生菌和植物提取物的膳食补充剂
CN105969700B (zh) * 2016-07-15 2019-05-17 江南大学 一种具有吸附锰离子功能的植物乳杆菌及其应用
TWI632236B (zh) * 2017-08-03 2018-08-11 光晟生物科技股份有限公司 加氏乳酸桿菌br-0121及其用途
CN107699503B (zh) * 2017-11-22 2020-06-09 内蒙古农业大学 一种异常威克汉姆酵母bt-1-1及其用途
CN108277179B (zh) * 2018-03-07 2021-08-03 武汉生物样本库有限公司 一种枯草芽孢杆菌的高密度发酵及喷雾干燥方法
CN108753307A (zh) * 2018-06-08 2018-11-06 合肥净龙环保科技有限公司 一种用于治理铅污染土壤的修复剂
TWI689584B (zh) * 2018-11-17 2020-04-01 原生生物醫學股份有限公司 新穎乳酸菌及其用以治療或預防重金屬相關疾病之用途
CN110089666B (zh) * 2019-05-16 2024-01-12 内蒙古大学 一种植物乳杆菌及其胞外多糖
CN110122764A (zh) * 2019-06-11 2019-08-16 深圳保时健生物工程有限公司 一种婴幼儿辅食及其应用
CN110575816B (zh) * 2019-06-19 2022-04-05 北京工商大学 一种高吸附、高耐受重金属铅的植物乳杆菌yw11
CN111096459B (zh) * 2019-11-19 2022-08-02 西南大学 植物乳杆菌lp33在制备用于预防铅中毒的产品中的应用
CN111040960B (zh) * 2019-11-19 2022-02-01 西南大学 植物乳杆菌lp33及其在制备用于促进铅排泄的产品中的应用
CN111012804B (zh) * 2019-12-16 2022-05-17 南京大学 益生菌矿物材料复合制剂、矿物材料在制备抑制恶性肿瘤生长药物中的应用
CN111334455B (zh) * 2020-03-13 2022-04-15 江南大学 一种丝状真菌抑制剂及其应用
AU2020438735B2 (en) * 2020-03-26 2024-05-02 Native Biomedicals Ltd. Novel Lactobacillus plantarum and lactic acid bacteria composition and use thereof for treating or preventing heavy metal related diseases
CN111826324A (zh) * 2020-08-05 2020-10-27 厦门惠盈动物科技有限公司 一种鼠李糖乳杆菌菌粉的制备方法
CN111758940A (zh) * 2020-08-18 2020-10-13 眉山市产品质量监督检验所 一种降低叶类和豆类泡菜铅含量的方法
CN112111430B (zh) * 2020-09-27 2022-10-21 吉林农业大学 一种抗氧化与抗衰老双效益生菌及其应用
CN112708583B (zh) * 2021-01-29 2022-05-17 重庆第二师范学院 一种发酵乳杆菌lf-schy34及其应用
CN113262242B (zh) * 2021-07-16 2021-11-05 山东中科嘉亿生物工程有限公司 一种乳双歧杆菌jybr-190在排除体内重金属产品中的应用
CN114317621B (zh) * 2021-10-15 2024-03-12 重庆医药高等专科学校附属第一医院(重庆市职业病防治院重庆市第六人民医院重庆市中毒控制中心) 一种乳酸杆菌代谢产物及其制备方法和应用
CN114164149B (zh) * 2021-11-29 2023-10-03 南昌大学 一株缓解肥胖和铅毒性的植物乳杆菌p101及其应用
CN115975856B (zh) * 2022-09-30 2025-03-14 成都大学 类肠膜魏斯氏菌在吸附金属铅中的应用
CN115479798A (zh) * 2022-10-31 2022-12-16 南京大学 降低儿童土壤铅生物有效性的方法
CN116327659A (zh) * 2023-04-08 2023-06-27 河北圣奥化妆品有限公司 一种黄瓜植物酵素的制备方法及含有该酵素的面膜
CN119662476A (zh) * 2024-12-20 2025-03-21 宁波希诺亚海洋生物科技有限公司 一株海洋来源的鼠李糖乳杆菌及其应用
CN119506172A (zh) * 2025-01-15 2025-02-25 青岛农业大学 一株高盐低pH下有效富集去除镉的植物乳杆菌及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1506070A (zh) 2002-12-10 2004-06-23 西安大鹏生物科技股份有限公司 一种含水苏糖的排铅保健品
CN101011432A (zh) 2007-01-26 2007-08-08 陈乃富 蕨菜黄酮提取物作为排铅和缓解铅中毒药物中的应用
CN101134945A (zh) 2007-05-21 2008-03-05 大连民族学院 一种优势菌及用于含铅废水的处理
CN101252943A (zh) 2005-07-05 2008-08-27 普罗比公司 乳杆菌用于增加选自铁、锌、钙的金属及其离子的吸收的用途
CN101933937A (zh) 2010-07-13 2011-01-05 范晓青 低分子柑橘果胶在排铅排重金属临床中的应用
CN102296046A (zh) * 2011-09-16 2011-12-28 广州市暨源生物科技有限公司 可用于预防慢性重金属中毒的重组食品级乳酸菌、其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101368165B (zh) * 2008-08-12 2011-01-12 辽宁医学院 一种用于畜禽日粮中添加的益生菌组合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1506070A (zh) 2002-12-10 2004-06-23 西安大鹏生物科技股份有限公司 一种含水苏糖的排铅保健品
CN101252943A (zh) 2005-07-05 2008-08-27 普罗比公司 乳杆菌用于增加选自铁、锌、钙的金属及其离子的吸收的用途
CN101011432A (zh) 2007-01-26 2007-08-08 陈乃富 蕨菜黄酮提取物作为排铅和缓解铅中毒药物中的应用
CN101134945A (zh) 2007-05-21 2008-03-05 大连民族学院 一种优势菌及用于含铅废水的处理
CN101933937A (zh) 2010-07-13 2011-01-05 范晓青 低分子柑橘果胶在排铅排重金属临床中的应用
CN102296046A (zh) * 2011-09-16 2011-12-28 广州市暨源生物科技有限公司 可用于预防慢性重金属中毒的重组食品级乳酸菌、其制备方法与应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ELLMAM, G.C.: "Tissue sulfhydryl groups", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 82, no. 1, pages 70 - 77
See also references of EP2708599A4
WANG, HAI-TAO ET AL.: "Safe and Selective Compositions Screened for Specific Microbial Biosorption Capability to Heavy Metal Lead", FOOD SCIENCE, vol. 28, no. 11, 30 December 2007 (2007-12-30), pages 390 - 396, XP008170760 *
YEAGER D.W.; CHOLAK J.; HENDERSON E.W.: "Determination of lead in biological and related materials by atomic absorption spectrometry", ENVIRONMENTAL SCIENCE AND TECHNOLOGY, vol. 5, 1971, pages 1020 - 1022

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107129951A (zh) * 2017-06-19 2017-09-05 青岛科拓恒通乳酸菌产业化开发研究院有限公司 一种提高盐碱地花生微量养分利用率的复合乳酸菌制剂及其应用
CN107129951B (zh) * 2017-06-19 2020-07-07 青岛科拓恒通乳酸菌产业化开发研究院有限公司 一种提高盐碱地花生微量养分利用率的复合乳酸菌制剂及其应用
CN115838650A (zh) * 2022-05-06 2023-03-24 佛山市孛特碧欧微生物科技有限公司 植物乳杆菌及其应用

Also Published As

Publication number Publication date
US9320766B2 (en) 2016-04-26
US20140369981A1 (en) 2014-12-18
EP2708599A1 (en) 2014-03-19
EP2708599B1 (en) 2016-05-04
CN102586148B (zh) 2013-05-08
CN102586148A (zh) 2012-07-18
EP2708599A4 (en) 2015-09-09

Similar Documents

Publication Publication Date Title
WO2013127146A1 (zh) 一种能够缓解铅毒性的植物乳杆菌及其用途
US9451781B2 (en) Strain of cadmium-removing Lactobacillus plantarum bacterium, and uses of the same
CN111406856B (zh) 一种解酒护肝功能性发酵饮料及其制备方法
CN109628358B (zh) 一种复合益生菌及其应用
US11291697B2 (en) Probiotic composition and use thereof
CN103756926B (zh) 一种能够缓解铜毒性的植物乳杆菌及其用途
CN102174450B (zh) 一种抗幽门螺杆菌感染的植物乳杆菌及其用途
CN112244299B (zh) 一种具有缓解非酒精性脂肪肝功能的益生菌组合物及其制备方法
CN111996153B (zh) 一种短双歧杆菌及其应用
CN106834187A (zh) 一种两歧双歧杆菌及其用途
CN117487683A (zh) 具有抗幽护胃和消食化积功效的益生菌组合物及其应用
JP6039638B2 (ja) アディポネクチン分泌促進及び/又は減少抑制剤
CN104611278B (zh) 一种能够缓解铝毒性的植物乳杆菌及其用途
CN102618452B (zh) 唾液乳杆菌及其代谢物的制备方法和组合物以及应用
CN111387383A (zh) 一种具有减肥降脂功效的高多酚含量益生菌发酵苹果汁及制备方法
KR101640070B1 (ko) 신규한 바실러스 라이체니포미스 균주 및 이의 용도
CN108018243B (zh) 植物乳杆菌、复合益生菌枸杞子制品及其制备方法
CN118406590B (zh) 利用新型干酪乳酪杆菌株中药发酵及其应用
CN101574375B (zh) 一种乳酸菌保健胶囊及其制备方法
CN110859304A (zh) 一种葵盘降嘌呤酵素及其制备方法
CN117503834A (zh) 一种健胃消食的中药发酵制剂及其制备方法
CN117660246A (zh) 一株高产代谢酶的乳酸乳球菌乳亚种s28及其应用
CN105661239A (zh) 一种绿豆玉米发酵汁及其制备方法
CN120485054A (zh) 一种嗜酸乳杆菌cbbm004及其在肠道保健、肾脏保健、降血糖产品中的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12869827

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14118867

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2012869827

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE